The Big Biz Show interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals, discussing suicidal ideation, NRx-100 and IV Ketamine.
David Meltzer of “Office Hours” interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals to discuss the anti-depressant effect of Ketamine.
Jonathan Javitt, MD, MPH, Founder, Chairman, and Chief Scientist of NRx Pharmaceuticals, gives the keynote address “Ketamine for Suicidal Depression: The Benefits are Clear, But So are the Risks,” at the Sachs Neuroscience Innovation Forum in San Francisco, CA on January 7, 2024.
The Big Biz Show interviews Jonathan C. Javitt, M.D., M.P.H., Chairman and Chief Scientist, NRx Pharmaceuticals, discussing the anti-depressant effect of Ketamine.
The Big Biz Show interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals, discussing NRx-101 – the first investigational drug in FDA trials for suicidal bipolar depression.
Veteran broadcaster Jane King from the NASDAQ MarketSite in Times Square interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals, discussing NRx-101 – the first investigational drug in FDA trials for suicidal bipolar depression.
On November 16th, Dr. Jonathan Javitt joined Steve Darling from Proactive to discuss groundbreaking developments in the treatment of suicidal ideation and depression.
World Bipolar day is celebrated on March 30, the birthday of Dutch artist Vincent Van Gogh who died by suicide at 37 and was posthumously diagnosed as probably having a bipolar disorder. Bipolar disorder is a brain disorder that causes changes in a person’s mood, energy and ability to function.
NRx Pharmaceuticals, Inc. today announced that it had a meeting and a written response from the Food and Drug Administration (FDA) last week regarding its lead compound, NRX-101.
